Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Barasertib (AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo.

Barbara A Helfrich[1], Jihye Kim[1], Dexiang Gao[2,3], Daniel C Chan[1], Zhiyong Zhang[1], Aik-Choon Tan[1], Paul A Bunn Jr[1].

Authors' Affiliations: University of Colorado Cancer Center and Departments of [1]Medicine, [2]Dept of Biostatistics & Informatics; and [3]Dept of Medicine-Pediatrics, University of Colorado Denver-Anschutz Medical Center.

12801 E 17th Ave, Aurora, CO 80028

Grant Support: Studies were supported by a NCI SPORE P50-CA058187 awarded to P. A. Bunn and a research contract from AstraZeneca awarded to P. A. Bunn. The Cancer Center Shared Resources are supported by NIH grant 2-P30-CA46934.

Running Title: Barasertib inhibits the growth of small cell lung cancer cell lines

Keywords: SCLC, AURKB, barasertib, MYC amplification, ploidy

Corresponding author:

Paul A. Bunn, Jr., MD

University of Colorado Denver-AMC

12801 E 17th Ave, MS8117

Aurora, CO 80045

Phone: 303-724-4498

FAX: 303-724-3889

Email: Paul.Bunn@ucdenver.edu

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Conflict of Interest: AstraZeneca provided partial funding for these studies through a sponsored research agreement. The authors have no stock or commercial involvement with AstraZeneca.

Abbreviations:

SCLC small cell lung cancer

Rb retinoblastoma

HQPA hydroxyquinazoline pyrazol anilide

ATCC American Type Culture Collection

AURKA aurora kinase A

AURKB aurora kinase B

CCLE Cancer Cell Line Encyclopedia

GEO Gene Expression Omnibus

MTS 3-(4-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl-2H-tetrazolium

p-H3 phosphorylated histone H2

PI propidium iodine

IACUC Institutional Animal Care and Use Committee

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Abstract:

Small cell lung cancer (SCLC) cells have rapid proliferation, universal Rb inactivation and high rates of *MYC* family amplification, making aurora kinase inhibition a natural target. Preclinical studies have demonstrated activity for Aurora A and pan Aurora inhibitors with some relationship to MYC family expression. A clinical trial showed activity for an Aurora kinase A inhibitor but no biomarkers were evaluated. We screened a panel of 23 SCLC lines with and without *MYC* family gene amplification or high *MYC* family gene expression for growth inhibition by the highly potent, selective aurora kinase B inhibitor barasertib. Nine of the SCLC lines were very sensitive to growth inhibition by barasertib with IC_{50} values of < 50 nM and > 75% growth inhibition at 100 nM. Growth inhibition correlated with *cMYC* amplification (p = 0.018) and *cMYC* gene expression (p = 0.026). Sensitive cell lines were also enriched in a published *MYC* gene signature (p = 0.042). *In vivo* the barasertib inhibited the growth of xenografts established from a SCLC line which had high *cMYC* gene expression, no *cMYC* amplification and was positive for the core MYC gene signature. Our studies suggest that SCLC tumors with *cMYC* amplification/high gene expression will frequently respond to Aurora B inhibitors and that clinical studies coupled with predictive biomarkers are indicated.

Introduction:

Small cell lung cancer, accounting for approximately 35,000 cases annually, is the sixth most common cause of cancer deaths in the U.S. (1). Clinically SCLC tumors have rapid doubling times and a propensity for early development of widespread metastatic disease (2). The overall 5-year survival from diagnosis is less than 5% despite high initial response rates to first-line chemotherapy of 70-90% (2, 3).

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

There have been few therapeutic advances in the treatment of SCLC in recent decades and SCLC remains a major public health problem. The standard of care for both limited stage (IIB-III) and extensive stage (IV) has been the drug combination of etoposide with cisplatin or carboplatin since the early 1980's (4). Modest improvements in survival have come from the addition of chest radiotherapy in limited stage. Studies evaluating new generation cytotoxic chemotherapies have not had a significant impact on the standard of care and topotecan is the only cytotoxic currently approved for the treatment of relapsed SCLC (5, 6). Biological studies have shown that loss of the *Rb* and *p53* tumor suppressor genes is universally present in SCLC cells (7, 8). In addition, a significant proportion of SCLC's have amplification of various *MYC* family members (9).

A recent biological approach to cancer has been the development of small molecules targeting the key mitotic regulatory serine/threonine kinases Aurora A (AURKA) and Aurora B (AURKB) which are frequently overexpressed in lung cancer (10, 11). During mitosis AURKA and AURKB coordinate cell cycle progression through G2/M. AURKA regulates centrosome maturation and separation, bipolar spindle assembly and mitotic entry (12). AURKB plays a critical role by regulating chromosome alignment, accurate segregation, and cytokinesis by its movement through the mitotic stages (12). In a human colon carcinoma cell lines, AURKB inhibition by barasertib resulted in Rb hypophosphorylation leading to polyploidy after an aberrant mitosis (13). The phenotypic result of AURKB inhibition is an induction of polyploidy, a hallmark of antitumor activity.

Currently aurora kinase inhibitors are in clinical trials, however, predictive biomarkers for patient selection are needed (14). In a recent pharmacological screen of 34 SCLC lines for growth inhibition by the AURKA inhibitor MLN8237 and the dual

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Aurora A/B inhibitors PHA680632, VX680 and ZM447739, six SCLC lines that had 50% growth inhibitory concentrations (IC_{50}) of < 1 μM to all four drugs were considered sensitive and response was correlated with amplification of the *cMYC* oncogene (15). However, there were several lines with *cMYC* amplification that did not respond and several other lines without *cMYC* amplification that were sensitive. Furthermore, amplification of *MYC* family members *MYCL1* and *MYCN* did not correlate with sensitivity to dual Aurora A/B inhibitors or the AURKA inhibitor MLN8237 (15). A phase I clinical trial reported activity of MLN8237 in 21% of relapsed SCLC patients, however, *cMYC* expression was not evaluated (16).

In contrast, growth inhibition by the dual Aurora A/B inhibitor PF-03814735 in a panel of 20 SCLC lines correlated with amplification or overexpression of any of the *MYC* family members (*cMYC*, *MYCL1* and *MYCN*) (17). In this study 14 SCLC lines with IC_{50s} < 100 nM were considered sensitive. Again there were SCLC lines with no evidence of *MYC* family amplification or overexpression that were sensitive to PF03814735. Resistance was defined as an IC_{50} of > 3 μM and no *MYC* family amplification was found in these resistant lines. PF0381475 inhibited the *in vivo* growth of c*MYC* and *MYCN* amplified cell lines in SCLC tumor xenograft models (17). These studies suggest that there is some link between MYC family members and the Aurora kinases A & B in SCLC but no studies of specific aurora kinase B inhibitors have been reported.

MYC family gene amplification in conjunction with mutation/deletion of the tumor suppressor genes *TP53* and *RB1* are the most frequently altered genes in SCLC (7-9). Focal amplification of the *MYC* family of transcription factors including *cMYC*, *MYCL1* and *MYCN* has been found in about 30% of SCLC samples and amplification of *MYCL1* and *MYCN* are found exclusively in neuroendocrine tumors including SCLC (18). A recent report using chromogenic in situ hybridization evaluated *cMYC* amplification in 77

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

formalin-fixed paraffin-embedded tumor samples from SCLC patients who had a diagnostic biopsy for SCLC (19). *cMYC* amplification was found in 20% of the biopsies and was associated with poor survival. Furthermore, p53 proteins with missense mutations have been shown to transactivate *cMYC* through the C-terminus (20).

In both of the above reports, the associated phenotypic drug induced changes by the aurora kinase inhibitors, including increased G2/M arrest, polyploidy and a decrease in histone H3 phosphorylation, were thought to be primarily due to inhibition of AURKB (15, 17). We therefore evaluated barasertib, an AURKB specific inhibitor, in a panel of 23 SCLC lines with and without *MYC* family amplification.

Materials and Methods:

Reagents. Barasertib and barasertib-HQPA were provided by Astra Zeneca Pharmaceuticals (Macclesfield, Cheshire, UK). The structure of barasertib was previously published (21). Barasertib is rapidly converted by plasma phosphatases to the active barasertib-HQPA metabolite. Therefore, *in vitro* studies were conducted with barasertib-HQPA and *in vivo* experiments with barasertib (21). The barasertib-HQPA IC_{50} for AURKB is 0.37 nM versus 1369 nM for AURKA (21).

SCLC cell lines. The SCLC lines H82, H146, H187, H211, H345, H378, H446, H524, H526, H748, H774, H841, H889, H1092, H1694, H1963, H2029, H2081, H2141, H2171 and N417 were obtained from Drs. Adi Gazdar and John Minna UTSouthwestern, Dallas, TX) and deposited in the UCCC Tissue Culture Core. Authentication of the cell lines by short tandem repeat (STR) DNA profiling was through the Tissue Culture Core and the UCCC DNA Sequencing and Analysis Core. The DMS114 and H69 lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). All cell lines were used within 6 months of resuscitation of a frozen vial from the authenticated passage. The clinical characteristics of the patients from whom the cell lines were derived are shown in Table 1 (22). All cell lines were mycoplasma free and maintained

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

in RPMI-1640 + 5% or 10% FBS at 37C in 5% CO_2. The cell lines were obtained in 1993 (H146, H187, H211, H345, H378, H446, H524, H526, H748, H774 and H841), 2011 (DMS114), and 2014 (H69, H82, H889, H1092, H1694, H1963, H2029, H2081, H2141, H2171, and N417).

***MYC* family gene amplification, gene expression and *MYC* core gene signature**. Cell line *MYC* family amplification (15, 17), *MYC* family gene expression (Cancer Cell Line Encyclopedia, accession number GSG36133, (broadinstitute.org) and the *MYC* core gene signature (Gene Expression Omnibus (GEO, accession number GSE15523) (ncbi.nlm.nih.gov) (23) were used to determine if they related to cell line sensitivity to barasertib.

***Aurora A/B* gene and Aurora B protein expression by western.** *AURKA and AURKB* gene expression in our panel of 23 SCLC lines is shown in Supplemental Figure 1A-B. Gene expression data was from the CCLE (accession number GSE36133) and was significantly higher than in 17 normal epithelial airway samples (accession number GSE24337) ($p < 0.001$). We confirmed AURKB protein expression by western blotting in a subset of SCLC lines (Supplemental Figure 1C). Cell lysates were prepared in Triton-X100 lysis buffer, sonicated and protein concentration determined by *DC* Protein Assay (Bio-Rad, Hercules, CA). Protein (50 µg) were resolved by SDS-PAGE. Gels were electroblotted onto PVDF membranes and probed for AURKB (Cell Signaling Technology, Danvers, MA). Protein bands were visualized by chemiluminescence using SuperSignal West Femto (Thermo Scientific, Rockford, IL). β-actin (Cell Signaling Technology) served as a loading control. AURKB protein expression was similar across the SCLC lines.

Modified Tetrazolium Growth Assays. Inhibition of cell growth by was assessed using MTS (CellTiter Aqueous One Solution, Promega, Madison, WI) (24). Briefly, 2,000 to

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

10,000 viable cells were plated in growth medium in 96-well plates (Corning, Ithaca, NY) and incubated overnight at 37^0C. Barasertib-HQPA, 0 to 100 nM, was added and plates were incubated for 5 days, after which the MTS was added and the absorbency of each well was measured at 490 nm using an automated plate reader (Molecular Devices, Sunnyvale, CA).

Immunofluorescence staining phosphorylated histone H3 (p-H3). p-H3 (Ser10) expression was determined by FACs analysis. Briefly, cells were fixed with 4% formaldehyde at 37^0C for 10 minutes and then chilled on ice for 1 minute. Fixed cells were permeabilized on ice for 30 minutes in ice cold 90% ethanol and then blocked in 0.5% bovine serum albumin for 10 minutes at room temperature (RT). The fixed-permeabilized-block cells were stained for 60 minutes at RT followed by 3x washes. Primary antibody was a rabbit monoclonal antibody to phosphorylated Histone H3 (Ser10) directly conjugated with Alexa Fluor 488 (Cell Signaling Technology, Danvers, MA) and the isotype control was a rabbit IgG directly conjugated with Alexa Fluor 488 (Cell Signaling). Cell fluorescence was measured by FACS (Beckman FC500, Beckman Coulter, Hiahleah, FL). The percentage of positive p-H3 (Ser10) cells was determined using the Coulter software.

Ploidy Analysis. Briefly, 300,000 cells were exposed to barasertib-HQPA 30 nM or 50 nM for 24 and 48 hours then stained with saponin, propidium iodine (PI) and RNAaseA solution overnight. Alterations in DNA ploidy were determined by flow cytometry. Doublet cells were gated out of the analysis. Remaining cells were analyzed on a log2 scale to determine the percentage of the population that was tetraploid (DNA content 4N) and the subsequent accumulation of ploypoid cells (DNA content ≥ 8N).

Nude mouse xenograft tumor model. Athymic nude mice (4 to 6 week old females) obtained from the National Cancer Institute (Bethesda, MD) were maintained in the

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

University of Colorado Denver Animal Resources Center with an approved protocol by IACUC. The SCLC line H841 was mixed with an equal volume of cold Matrigel and implanted at 5 million cells in 100 µL in the rear flank. Treatment began on day 20 post tumor cell implantation. Mice were randomized into 8 mice per group and 5-7 of these that developed tumors treated with vehicle, barasertib at 50 or 100 mg/kg/day for 5 days, rested over the weekend and injected for 5 days the following week for a total of 10 days of treatment. Tumor volumes were measured 3x a week with a digital caliper.

Statistical methods. Fisher's exact test was used to determine the correlation between gene amplification of *MYC* family members and sensitivity to growth inhibition by barasertib-HQPA. Fisher's exact test was also used to determine the correlation between a published *MYC* gene signature and growth inhibition (23). A two-group t-test (gene expression as a continuous variable) and an odds ratio estimate (dichotomized gene expression) were used to determine a correlation between *MYC* family gene expression and growth inhibition. Linear mixed regression models were used to analyze the association between log tumor volumes and barasertib treatment over time.

Results:

In vitro growth inhibition by barasertib-HQPA. We evaluated the growth inhibitory effects of barasertib-HQPA on 6 *cMYC* amplified, 7 *MYCL1* amplified, 2 *MYCN* amplified and 8 SCLC lines with no *MYC* family amplification (Table 1). Barasertib-HQPA concentrations evaluated were 0 - 100 nM ensuring that AURKA was not inhibited. The barasertib-HQPA concentrations were similar to those used in other preclinical studies and exceeded the trough levels achieved in human trials (25, 26).

As shown in Figure 1, we found three patterns of growth inhibition. Pattern A, (Figure 1A), included 9 SCLC lines that were the most sensitive to barasertib-HQPA. The growth inhibition IC_{50} concentration for all 9 lines was < 50 nM and at 100 nM

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

barasertib-HQPA growth inhibition was > 75%. *cMYC* was amplified in 5 of these lines, 2 lines were *MYCL1* gene amplified and 2 lines had no *MYC* family amplification.

The 10 SCLC lines shown in Figure 1B were classified as having intermediate sensitivity to barasertib-HQPA as growth inhibition at 100 nM was 32% - 50%. Increasing the barasertib-HQPA concentration to 1 μM did not increase growth inhibition (data not shown). One cell line with intermediate sensitivity was *cMYC* amplified, 4 lines were *MYCL1* amplified, 2 lines had *MYCN* gene amplification and 3 lines had no *MYC* family amplification.

The 4 SCLC lines shown in Figure 1C were classified as resistant to barasertib-HQPA as growth inhibition at 100 nM was < 20% and increasing the concentration to 1 μM did not alter the growth inhibition (data not shown). Three resistant lines had no *MYC* family amplification and 1 line was *MYCL1* gene amplified.

Relationship of barasertib-HQPA growth inhibition to *MYC* family gene amplification. As shown in Figure 1A-C, 6 cell lines were *cMYC* amplified of which 5 were sensitive. Seventeen cell lines were not *cMYC* amplified of which 4 were sensitive. Thus, there was a significant association between sensitivity to growth inhibition by barasertib-HQPA and *cMYC* amplification ($p = 0.018$). The odds of being sensitive was 16 time higher (95% CI, 1.4, 183) for *cMYC* amplified SCLC lines compared to non-*cMYC* amplified cell lines. The association between *MYCL1* gene amplification and growth inhibition was not significant ($p = 0.2$). Since there were only 2 *MYCN* amplified lines and both had intermediate sensitivity we did not evaluate this as a separate group. There was also no significant association between sensitivity to barasertib-HQPA and having any *MYC* family gene amplification ($p = 0.4$).

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Relationship of barasertib-HQPA growth inhibition to *cMYC* gene expression.

We next determined if there was an association between *cMYC* gene expression and sensitivity to growth inhibition by barasertib-HQPA (Table1; Figure 2A). The mean *cMYC* gene expression in sensitive lines (10.9 ± 4) was higher than the mean *cMYC* gene expression of the intermediate/resistant lines (7.2 ± 3.3). The *cMYC* gene expression was high (>10) in 11 cell lines of which 7 were sensitive and the *cMYC* gene expression was low (<7.5) in 12 cell lines of which 2 were sensitive to barasertib-HQPA. This difference was significant (p = 0.026).

There was no significant association between the mean *MYCL1* gene expression in the sensitive cell lines (8.4 ± 2.7) and the intermediate/resistant lines (9.8 ± 2.8; p = 0.28). There was also no significant association between the mean *MYCN* gene expression in the sensitive cell lines (5.3 ± 0.67) and the intermediate/resistant lines (6.7 ± 3; p = 0.13).

We then separated the cell lines into two groups based on *cMYC* gene expression modeled as a categorical variable based on quartile cutoff values of the initial distribution of being sensitive, intermediate or resistant to growth inhibition by barasertib-HQPA. Categories were combined if similar coefficients were observed. The best functional form of *cMYC* gene expression was the dichotomized variable with two categories at the cutoff point of 12.9 (<12.9 vs ≥ 12.9), which corresponded to the 75th percentile of the *cMYC* gene. Based on this criteria, the odds of being sensitive was 11 times higher (95% CI, 1.2, 103) for cell lines with *cMYC* gene expression ≥ 12.9 compared to cell lines with *cMYC* gene expression < 12.9.

As shown in Figure 2B, we analyzed our cell line panel for the expression of a core *MYC* gene signature (23). The *cMYC* signature was present in 9 cell lines of which 6 were sensitive to barasertib-HQPA. The *cMYC* gene signature was absent in 14 cell

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

lines of which 3 were sensitive to barasertib-HQPA. All 5 *cMYC* gene amplified lines that were sensitive to growth inhibition by barasertib-HQPA expressed the core *MYC* gene signature as did the H524 *cMYC* amplified line which was intermediate in growth inhibition. None of the 7 *MYCL1* amplified lines expressed the core *MYC* gene signature including the H378 and H1963 lines which were sensitive to growth inhibition. The 2 *MYCN* amplified lines were both intermediate to growth inhibition and the H526 was positive for the core signature and the H69 was negative. Two of the 8 SCLC lines that did not have *MYC* family gene amplification were positive for the *MYC* core gene signature and the H841 line was sensitive to growth inhibition and the DMS114 was intermediate. The remaining 6 SCLC lines without *MYC* family amplification were negative for the core *MYC* gene signature. The H2081 line was sensitive to growth inhibition by barasertib-HQPA and the remaining 5 lines were intermediate or resistant to growth inhibition. There was a statistically significant correlation between expression of the *MYC* core gene signature and sensitivity to growth inhibition by barsertib-HQPA ($p = 0.042$) although this correlation was not superior to the use of *cMYC* gene expression ($p = 0.026$) or amplification ($p = 0.018$).

Barasertib-HQPA inhibited phosphorylation of histone H3. To ensure that resistance to growth inhibition by barasertib-HQPA was not due to lack of drug uptake by the cell lines, we evaluated phosphorylated histone H3 (Ser10) by flow cytometry. Phosphorylation on histone H3 (Ser10) by AURKB is required for chromosome condensation during mitosis (27). The fraction of detectable cells with phosphorylated H3 (Ser10) was very low in untreated SCLC lines (data not shown). Therefore, we treated the SCLC lines with paclitaxel for 24 hours to arrest the cells in the G2/M phase of the cell cycle increasing the fraction of cells with phospho-H3 (Ser10). As shown in Figure 3, a concurrent 24 hour treatment with paclitaxel and barasertib-HQPA reduced the fraction of phosphorylated H3 (Ser10) positive cells induced by paclitaxel alone.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

This demonstrated that barasertib-HQPA actively inhibited the kinase activity of AURKB in cell lines both sensitive (Figure 3A, H446) and resistant (Figure 3B-C, H345 & H748) to barasertib-HQPA induced growth inhibition suggesting that drug uptake does not explain the difference. While it is possible that barasertib-HQPA could be less stable in the resistant lines during a longer exposure, it has been shown to be stable for > 72 days at pH7.4 and the extrapolated half-life at pH1 is > 11.4 days (personal communication on July 12, 2016 Dr. Sue Ashton, AstraZeneca, Macclesfield, Cheshire, UK).

Barasertib-HQPA induced polyploidy. The induction of polyploidy (DNA content ≥8N) is the hallmark of phenotypic changes induced by AURKB inhibition as the cells re-enter the S-phase of the cell cycle without going through cytokinesis (28). We evaluated the degree of polyploidy at 24 and 48 hours post-treatment with 30 or 50 nM barasertib-HQPA in 10 SCLC lines representing lines with *cMYC, MYCL1, MYCN* amplification, and no *MYC* family amplification, and that were sensitive, intermediate or resistant to growth inhibition by barasertib-HQPA (Table 2).

After exposure to 30 nM barasertib-HQPA the sensitive cell lines H378, H841, H211 and H446 had a significant increase in the fraction of 4N cells at 24 hours and the fraction of 8N cells at 48 hours (Table 2). Similarly, in the intermediate lines H69, H146, H187 and H524 the fraction of 4N cells was significantly increased at 24 hours and the fraction of 8N cells increased at 48 hours.

While the time course for the appearance of a tetraploid peak followed by a polyploid peak was consistent across the above cell lines, this was not the scenario in the more resistant lines. The H345 cell line was initially treated with 30 nM barasertib-HQPA and as shown in Table 2 despite an increase in the fraction of 4N cells there was no increase in the 8N cell fraction. Subsequently we treated H345 and the other resistant cells lines DMS53, H774 and H748 with 50 nM barasertib-HQPA as shown in

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Table 2 the cell lines remained 4N following 48 hours of treatment. In summary, cytokinesis failure in the cell lines sensitive and intermediate to growth inhibition by barasertib-HQPA resulted in DNA endoreduplication and the appearance of polyploid cells (DNA content 8N). In contrast the resistant cell lines H345, DMS53, H774 and H748 remained in a tetraploid state did not reentered the S-phase and did not undergo endoreduplication.

Barasertib inhibited tumor xenografts. We evaluated the *in vivo* efficacy of barasertib on the SCLC line H841 (no *cMYC* family amplification, high *cMYC* gene expression and positive for the *MYC* gene expression signature). In the *in vitro* growth inhibition assays described above we demonstrated that 100 nM barasertib-HQPA inhibited the growth of the H841 by 85%. The H841 cells were implanted subcutaneously in nude mice and treated with barasertib at 50 or 100 mg/kg/day Monday-Friday for 2 weeks. The barasertib doses were within the range previously published for *in vivo* studies of solid tumors and provided trough barasertib-HQPA serum concentrations above the concentrations used *in vitro* (29, 30).

As shown in Figure 4A, the H841 xenografts were significantly growth inhibited during the 2-week barasertib treatment (days 20-31) compared with control mice. On day 34 the control mice were sacrificed due to tumor size. On day 34 the control tumors had a mean tumor volume of 2774 ± 2106 mm3 compared to 232 ± 186 mm3 in the 50 mg/kg treatment group ($p = 0.011$). The treatment groups were followed for an additional 30 days following cessation of treatment. At day 61, the mean tumor volume in the 50 mg/kg treatment group was 2828 ± 3670 mm3 comparable to the growth of the control tumors at sacrifice.

The 100 mg/kg barasertib dose caused H841 tumor xenograft regression and the tumors remained regressed through day 61 when the experiment was terminated. There

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

was no loss of weight throughout the course of treatment in treated animals compared to control mice (Figure 4B).

Discussion:

In this study we show that the specific AURKB inhibitor barasertib-HQPA has growth inhibitory effects in some SCLC lines and that *cMYC* amplification or high gene expression or *MYC* gene signature is a useful predictive biomarker. There has been little advance in the therapy of SCLC over the past three decades and new therapeutic options are urgently needed. The rapid growth and frequent over-expression of aurora kinases, which are key regulators of mitosis, has made aurora kinase inhibitors attractive targets for SCLC therapy. AURKB directly phosphorylates Rb at serine 780 playing a critical role in regulating postmitotic checkpoints to prevent polyploidy after an aberrant mitosis (13). In SCLC loss of Rb and p53 function is essentially universal leading to suppression of postmitotic checkpoints that prevent polyploidy after aberrant mitosis by eliciting a pseudo G1 arrest. Barasertib-HQPA was previously reported to induce polyploidy in tumor cells, providing rational for the study of barasertib-HQPA in SCLC (13). We report that polyploidy is induced in sensitive line but not in resistant lines.

Prior studies with dual aurora kinase A/B inhibitors and with specific AURKA kinase inhibitors demonstrated considerable activity in a small number of SCLC cell lines (15, 17). Growth inhibition by dual aurora A/B inhibitors and with AURKB knockdown has been correlated with *cMYC* amplification alone (15) and by other investigators with any *MYC* family amplification or high *MYC* family gene expression (17). Recently, it has also been shown through activity-based protein profiling that AURKB is a critical kinase in *cMYC* amplified SCLC cell lines but not in SCLC lines that lack *cMYC* amplification (31). Amplifications and overexpression of MYC family oncogenes has been reported in 15-30% of SCLCs (18, 19).

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

We report that 39% of the cell lines tested were sensitive to growth inhibition by barasertib-HQPA at concentrations that can be achieved in humans and do not inhibit AURKA. We found that *cMYC* amplification, *cMYC* gene expression and a *cMYC* gene signature were significant predictors of growth inhibition to barasertib-HQPA. The strongest association between growth inhibition was *cMYC* gene amplification (p=0.018) but *cMYC* gene expression (p=0.026) and *cMYC* gene signature (p=0.042) also correlated with growth inhibition. In addition, by an odds ratio estimate, *cMYC* amplified cell lines were 16 time more likely to be sensitive to growth inhibition by barasertib-HQPA than non-*cMYC* amplified cell lines. For *cMYC* gene expression the odds of being sensitive to growth inhibition was 11 times higher for cell lines with cMYC gene expression > 12.9. While the correlations between *cMYC* amplification, *cMyc* gene expression and *cMYC* gene signature and response to barasertib-HQPA are significant the sample size is small and should be confirmed in clinical trials where *cMYC* amplification status is assessed in all patients. Although there was some relationship to expression/amplification of other *MYC* family members and sensitivity to barasertib-HQPA, these correlations were not significant. However, in both our study and the studies of Sos et al there were *cMYC* amplified cell lines that were not sensitive to growth inhibition by AURKB or dual aurora kinase A/B inhibitors (15).

In contrast, Hook et al found significant association between IC_{50} values for the dual AURKA/AURKB inhibitor PF-3814735 and activation/amplification of any *MYC* family member (p=0.001) (17). We did not observe this with *MYCL1* amplification (p=0.2). There was also no significant association between sensitivity and being amplified for any *MYC* family (p = 0.4). We also did not find a statistically significant association between high *MYCL1* (p=0.28) or *MYCN* (p=0.12) gene expression and sensitivity to growth inhibition.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Further support of the potential combined predictive power of *cMYC* amplification/ high gene expression and the *MYC* core gene signature is evidenced by our *in vivo* experiments. We implanted the SCLC line H841 which has high *cMYC* gene expression, no *MYC* family amplification but was positive for the core *MYC* gene signature. This line was sensitive *in vitro* to growth inhibition by barasertib-HQPA, IC_{50} < 50 nM. Mice were dosed with either 50 or 100 mg/kg of the barasertib. The 50 mg/kg dose inhibited tumor growth however when treatment was stopped the tumors began growing. At the 100 mg/kg dose the H841 tumor regressed and remained regressed until the termination of the experiment.

Previous investigators evaluated the dual aurora A/B inhibitor PF-03814735 in mice bearing xenografts of the *cMYC* amplified SCLC line H82 and the *MYCN* amplified SCLC line H69 (17). Growth inhibition in the *cMYC* amplified H82 xenograft model was greater than in the *MYCN* H69 amplified xenografts. In our *in vitro* investigation of the efficacy of barasertib-HQPA, the *cMYC* amplified line H82 was sensitive to growth inhibition (IC_{50} < 30 nM) and the H69 *MYCN* amplified line had only intermediate sensitivity as at 100 nM barasertib-HQPA growth inhibition was 43%. The *cMYC* amplified line H82 was positive for the core *MYC* gene signature and the *MYCN* amplified H69 line was not.

There are some clinical data suggesting a role for aurora kinase inhibitors in SCLC. A phase II study of alisertib (AURKA inhibitor) given twice daily for 7 days every 21 days showed a response rate of 21% among 48 previously treated SCLC patients (16). Unfortunately, no biomarker correlates such as *cMYC* amplification or gene expression was determined. This alisertib phase II study was followed by a randomized global phase II trial of alisertib plus weekly paclitaxel versus placebo plus weekly paclitaxel in the second line setting. This trial has completed accrual but the results have not been reported. Unfortunately, *cMYC* amplification was not evaluated in this

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

study. Clinical studies of alisertib and other aurora kinase inhibitors have generally used a continuous dosing schedule largely based on preclinical studies with leukemia models. The early clinical studies using continuous dosing schedules reported myelosuppression as the dose limiting toxicities (16, 25-26). In our studies SCLC cell lines were growth inhibited with a single exposure *in vitro* and an intermittent exposure *in vivo*.

Recently AstraZeneca developed nanoparticles containing AZD2811 formerly known as barasertib-HQPA that increases biodistribution to tumor sites with minimal impact on bone marrow pathology resulting in lower toxicity and increased efficacy in multiple tumor models at half the dose intensity of barasertib (32). Thus, we believe that SCLC clinical trials with aurora kinase inhibitors such as AZD2811 using a panel of MYC biomarkers and intermittent drug scheduling studies should be done where a high dose is given intermittently as this maybe more effective and would allow recovery of the bone marrow. Support of an intermittent dosing schedule was also supported by an *in vivo* xenograft study using the *cMYC* amplified H82 SCLC line, where tumor growth control was more effective with a once weekly high dose 80 mg/kg (2x daily once for 3 weeks) of the dual A/B PF-03814735 inhibitor compared to a low dose daily schedule using 15 mg/kg (2x daily for 10 conservative days) (17). Furthermore, a high dose short course of barasertib therapy in a xenograft flank model using a *MYCN* overexpressing medulloblastoma model was efficacious at reducing tumor volume. Mice were dosed with barasertib at 50 mg/kg 2x daily for two days and tumor volumes were significantly different from 4 days after treatment until the end of the experiment ($p < 0.05$) (33). We believe that an AZD2811 clinical trial should be considered in SCLC patients who progress after etoposide/platinum doublet therapy with assessment of *cMYC* amplification and gene expression in all patients to determine the response rate in SCLC patients with and without *cMYC* amplification/gene expression. Alternatively, a “window

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

of opportunity" maintenance trial could be done after 4-cycles of etopside/cisplatin to determine time to progression in patients with and without *cMYC* amplification.

In conclusion, the AURKB inhibitor, barasertib-HQPA inhibited the growth of SCLC lines both *in vitro* and *in vivo*. Growth inhibition was greater in cell lines where barasertib-HQPA induced endoreduplication. Our studies suggest that SCLC tumors with *cMYC* amplification/high gene expression will frequently respond to Aurora B inhibitors and that clinical studies of the novel AZD2811 nanoparticle coupled with predictive biomarkers are indicated especially using an intermittent dosing schedule.

Acknowledgments: We thank the University of Colorado Cancer Center Flow Cytometry Shared Resources Core.

References:

1. Bunn PA, Minna JD, Augustyn A, Gazdar AF, Quadah Y, Krasnow MA, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thoracic Oncol 2016;11:453-74.

2. Kalemkerina GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ et al. Small cell lung cancer. J Natl Cmpr Cancer Netw 2011;9:1086-1113.

3. El Maalouf G, Rodier J-M, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer? Lung Cancer 2007;57(Supp1 2):S30-4.

4. Evans WK, Shepard FA, Feld R, Osoba D, Dang P, Doeboer G, et al. VP-16 and cisplatin as first-line therapy for small-call lung cancer. J Clin Oncol 1985;3:1471-7.

5. Rudin CM, Hann CI, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. J Natl Compr Can Netw 2008, ;6:315-22.

6. Metro G, Cappuzzo F. Emerging drugs for small-cell lung cancer. Expert Opin. Emerging Drugs 2009;14:591-604.

7. Voortman J, Lee J-H, Killian JK, Suuriniemi M, Wang Y, Lucchi M, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA 2010;107:13040-5.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

8. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28(2 Suppl):3-13.

9. Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes, Chromosomes & Cancer 2013;52:802-16.

10. Lok W, Klein RQ, Saif MW. Aurora kinase inhibitors as anti-cancer therapy. Anti-Cancer Drugs 2010;21:339-50.

11. Smith SL, Boweres NL, Betticher DC, Gautschi O, Ratschiller E, Hoban PR et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinomas is frequent, generally driven from one allele, and correlates with the level of genomic instability. Br J Cancer 2005;93:719-29.

12. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54.

13. Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, et al. Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell 2009;20:2218-28.

14. Lok W, Klein RQ, Saif MW. Aurora kinase inhibitors as anti-cancer therapy. Anti-Cancer Drugs 2010;12:339-50.

15. Sos ML, Dietlein F, Peifer M, Schottle J, Balke-Want H, Muller C, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 2012;109:17034-9.

16. Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EL, Kayaleh O, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol 2015;16:395-405.

17. Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 2012;11:710-19.

18. Brambilla E and Gazdar A. Pathogenesis of lung cancer signaling pathways; roadmap for therapy. Eur Respir J 2009; 1485-97.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

19. de Cassia S Alves R, Meurer RT, Roehe AV. MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study. J Cancer Res Clin Oncol 2014;140:2021-5

20. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP, et al. Activation of *c-myc* gene expression by tumor-derived p53 mutants requires a discrete c-terminal domain. Mol Cell Biol 1998;18:3735-43.

21. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann J-J M, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora kinase B. J Med Chem 2007;50:2213-2224.

22. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbonne DP, McClintock PR, et al. NCI-Navy Medical Oncology Branch Cell Line Data Base. J Cell Biochem Suppl 1996;24:32-91.

23. Chandriani S, Fregen E, Crowling VH, Pendergrass SA, Perou CM, Whitefield ML, et al. A core myc gene expression signature is prominent basal-like breast cancer but only partially overlaps with the core serum response. PLoS one 2009;e6693.

24. Cory AH, Owen TC, Barltrop JA, Corey JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Comm 1991; 3:209-12.

25. Kantargian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia0Manero G, Jabbour EJ, et al. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk 2013;13:559-567

26. Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 2013 31:370-380.

27. Perez-Cadahia B, Drobic B, Davie JR. H3 phosphorylation: dual role in mitosis and interphase. Biochem Cell Biol. 2009; 87:695-709.

28. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T et al. Aurora B couples chromosome alignment with anaphase targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161: 267-80.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

29. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, et al. Antineoplastic effects of an Aurora B inase inhibitor in breast cancer. Mol Cancer 2010; 9:42-55.

30. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Heptaology 2010;52:63-71.

31. Li J, B Fang B, Kinose F, Bai Y, Kim JY, Chen YA, et al. Target identification in small cell lung cancer via integrated phenotypic screening and activity-base protein profiling. Mol Cancer Ther 2016;15:334-42.

32. Ashton S, song YH, Nolan J, Cadogan E, Murray J, Odedra R, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med 2016;8:325ra17.

33. Diaz RJ, Golbourn B, Faria C, Picard D, Shih D, Raynaud D, et al. Mechanism of action and therapeutic efficacy of Aurora kinas B inhibition in MYC overexpressing medulloblastoma. Oncotarget 2015;6:3359-74.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Table 1. Cell Line Characteristics

Cell Line	Stage[1]	Gender[1]	PY[1]	Amplification[2]	*cMyc GE*[3]	*MYCL1 GE*[3]	*MYCN GE*[3]
H82	E	M	Unk	MYC	13.7	8.8	5.9
H211	E	F	35	MYC	13.2	5.9	6.7
H446	L	M	80	MYC	12.7	7.5	5.1
N417	Unk	F	Unk	MYC	13.7	6.1	5.5
H524	L	M	30	MYC	13.9	6.4	5.3
H2171	E	M	150	MYC	13.4	8	4.9
H378	E	F	50	MYCL1	3.8	13.1	5.1
H748	E	M	50	MYCL1	4.5	13.4	5.4
H1092	E	M	120	MYCL1	5	12.4	4.9
H1694	E	M	Unk	MYCL1	6.2	13.4	6.3
H1963	L	M	70	MYCL1	4.2	12.8	4.9
H2029	E	F	52	MYCL1	4.9	12.2	4.8
H2141	E	M	50	MYCL1	3.8	13.1	3.8
H69	E	M	Unk	MYCN	6	6.1	13.1
H526	E	M	30	MYCN	5.1	7.7	12.9
H146	L	M	100	None	11.8	5.7	5
H187	E	M	50	None	4.6	8.7	9.9
H345	L	M	60	None	7.2	9.9	6.5
H774	E	M	30	None	5.6	11.2	5.4
H841	L	M	70	None	10.6	7.4	5.1
H2081	E	F	25	None	12.9	6.3	4.8
DMS53	Unk	M	Unk	None	11.6	9.6	5
DMS114	Unk	M	Unk	None	10.8	7.1	5.1

[1] data obtained from reference 20. [2] Amplification status obtained from references 15, 17.
[3] MYC family gene expression was obtained from the Cancer Cell Line Encyclopedia (broadinstitute.org). Abbreviations: E=extensive stage; L=Limited stage; PY= pack year; GE= gene expression; Unk = unknown

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Table 2 Percent Ploidy Induced by barasertob-HQPA

Cell Line	Conc nM	Time	4N	≥8N	%GI 30 nM @ 120 H
H446 *cMYC* Amp	30	0H 24H 48H	31 75 11	6 10 71	55
H211 *cMYC* Amp	30	0H 24H 48H	24 80 19	1 5 41	75
H841 No Amp	30	0H 24H 48H	25 61 40	0 19 29	48
H378 *MYCL1* Amp	30	0H 24H 48H	28 44 55	0 0 11	72
H524 *cMYC* Amp	30	0H 24H 48H	22 53 55	0 2 24	36
H69 *MYCN* Amp	30	0H 24H 48H	44 82 38	3 7 58	35
H187 No Amp	30	0H 24H 48H	42 85 53	9 10 45	28
H146 No Amp	30	0H 24H 48H	40 72 45	7 9 45	26
H345 No Amp	30	0H 24H 48H	35 61 72	6 7 13	10
H345 No Amp	50	0H 24H 48H	41 40 65	3 4 6	10
DMS53 No Amp	50	0H 24H 48H	21 62 76	2 1 6	5
H774 No Amp	50	0H 24H 48H	22 31 58	2 2 3	10
H748 *MYCL1* Amp	50	0H 24H 48H	20 44 55	1 3 8	10

Abbreviations: Amp = amplification; H = hour; 4N = tetraploid DNA content; ≥8N = polyploid DNA content; ND = not done; GI = growth inhibition

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Figure Legends:

Figure 1. Growth inhibition by barasertib-HQPA in SCLC lines. The percentage growth inhibition compared to control was determined in MTS assays at 120 hours. A. These cell lines were classified as "sensitive" as the IC_{50} concentration was < 50 nM and growth inhibition at 100 nM was > 75%. B. These lines were classified as moderately resistant as growth inhibition as 100 nM growth inhibition was 32%-50%. C. These cell lines were classified as resistant as growth inhibition at 100 nM was < 20%.

Figure 2. *cMYC* gene expression and a core *MYC* gene signature correlated with growth inhibition by barasertib-HQPA in SCLC lines. A. The mean *cMYC* gene expression in the 9-SCLC classified as sensitive (S) was 10.9 (std 4) versus 7.6 (std 3.3) in the intermediate (I)/resistant (R) lines. By a two tailed-t test, the difference of 3.7 between sensitive and intermediate/resistant lines was significant (p = 0.026). *cMYC* gene expression was from the CCLE. B. There was a correlation between being positive for the *MYC* core gene signature and growth inhibition by barasertib-HQPA (p = 0.042).

Figure 3. Barasertib-HQPA inhibits the kinase activity of Aurora B in SCLC Lines that are sensitive H446 (3A) and resistant H345 (B) and H748 (3C) to growth inhibition. Cell lines were treated for 24-hours with paclitaxel to arrest the cells in G2/M increasing the fraction of phosphorylated Histone H3 (Ser10) cells. Concurrent treatment with equal concentrations of paclitaxel and barasertib-HQPA reduced the fraction of phosphorylated Histone H3. Analysis was by

intracellular staining with α-phosphorylated Histone H3 (Ser10) and analysis by flow cytometry.

Figure 4. A. The antitumor effects of the barasertib on H841 (No *MYC* family amplification, high *cMYC* gene expression, + for *MYC* gene expression signature) tumor xenotgrafts heterotransplanted into athymic nude mice. The mice were treated with 50 or 100 mg/kg for 5/7 days for two weeks. A. Significant tumor growth delay compared to

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

untreated control mice at day 34 post-tumor transplantation (time point at which control mice were sacrificed) was observed in the in vitro sensitive SCLC line H841 at the 50 mg/kg dose of barasertib (p=0.011). However, regrowth occurred once treatment was discontinued. Tumor regression was observed at the 100 mg/kg dose. B. Barasertib at 50 or 100 mg/kg had no deleterious effects on body weight.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.







Downloaded from mct.aacrjournals.org

2A.



2B.



Downloaded from mct.aacrjournals.org



Downloaded from mct.aacrjournals.org





Downloaded from mct.aacrjournals.org

Author Manuscript Published OnlineFirst on August 5, 2016; DOI: 10.1158/1535-7163.MCT-16-0298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

AACR American Association for Cancer Research

Molecular Cancer Therapeutics

Barasertib,(AZD1152)a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo

Barbara A Helfrich, Jihye Kim, Dexiang Gao, et al.

Mol Cancer Ther Published OnlineFirst August 5, 2016.

Updated version	Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-16-0298
Supplementary Material	Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2016/08/05/1535-7163.MCT-16-0298.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/early/2016/08/05/1535-7163.MCT-16-0298. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.

Downloaded from mct.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.